Announced details
Diseases with high unmet medical needs, antibody drug discovery, and bispecific antibody drug development
Aims to create bispecific antibody drug candidates during fiscal 2027
DDAIF (FRONTEO’s AI drug discovery platform) has been adopted by multiple major pharmaceutical companies
FRONTEO and Chiome Bioscience Inc. are conducting joint research. Capital and personal relationships: Not disclosed.
Headquartered in Shibuya-ku, Tokyo. Representative Director and President: Koike Masamichi (小池正道). A biotech venture engaged in antibody drug discovery, drug discovery support, and IDD (Integrated Drug Discovery). Other attributes: Not disclosed.
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Drug Discovery AI Factory（DDAIF）, DoppeLib™, Bispecific antibody drug candidates |
| Counterparty | Chiome Bioscience Inc. |
| Counterparty overview | Headquartered in Shibuya-ku, Tokyo. Representative Director and President: Koike Masamichi (小池正道). A biotech venture engaged in antibody drug discovery, drug discovery support, and IDD (Integrated Drug Discovery). Other attributes: Not disclosed. |
| Relationship with the Company | FRONTEO and Chiome Bioscience Inc. are conducting joint research. Capital and personal relationships: Not disclosed. |
| Launch date | The joint research started on 3 September 2026 (actual). |
| Applicable area | Diseases with high unmet medical needs, antibody drug discovery, and bispecific antibody drug development |
| Quantitative Effects | Aims to create bispecific antibody drug candidates during fiscal 2027 |
| Usage history | DDAIF (FRONTEO’s AI drug discovery platform) has been adopted by multiple major pharmaceutical companies |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To accelerate the creation of antibody drug candidates for diseases with high unmet medical needs by continuously advancing the discovery of new targets using AI and the production and validation of antibody candidates.